DOCSLIB.ORG

Herpes Zoster and Postherpetic Neuralgia Optimal Treatment

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Herpes Zoster and Postherpetic Neuralgia Optimal Treatment Drugs & Aging 1997 Feb; 10 (2): 80-94 DISEASE MANAGEMENT 11 7D-229X/97/0002-0080/S07.50/0 © Adis International Limited. All rights reserved. Herpes Zoster and Postherpetic Neuralgia Optimal Treatment Robert W. Johnson Pain Management Clinic, Bristol Royal Infirmary, and Department of Anaesthesia, University of Bristol, Bristol, England Contents Summary ........ ... ... .... ..... 80 1. The Size of the Problem . 81 2. Zoster-Associated Pain and Postherpetic Neuralgia (PHN) 81 3. Risk Factors for PHN . ... .. 82 4. Prevention of PHN ........ 82 5. Treatment of Acute Herpes Zoster 82 5.1 Antiviral Agents . 82 5.2 Corticosteroids . .. .. 84 5.3 Sympathetic Nerve Blockade . 85 6. Economic Considerations . 86 7. Assessment of PHN .... ... 86 8. Management of Established PHN 86 8.1 PhYSical Treatment . 87 8.2 Pharmacological Treatment 87 8.3 Psychosocial Treatment . 91 8.4 Neuroinvasive Measures . 91 8.5 Summary . 91 9. The Future . 92 Summary Herpes zoster is a common disease primarily affecting the elderly. Although some individuals experience no symptoms beyond the duration of the acute in­ fection, many develop chronic pain [postherpetic neuralgia (PHN)], which is the commonest complication of herpes zoster infection and remains notoriously dif­ ficult to treat once established. It may persist until death and has major implica­ tions for quality of life and use of healthcare resources. Predictors for the development of PHN are present during the acute disease and should indicate the need for the use of preventive therapy. At the present time, use of antiviral and certain tricyclic antidepressant drugs, combined with psycho­ social support, seem most effective, but are far from perfect. Sympathetic nerve blocks reduce acute herpetic pain but it is uncertain whether they prevent PHN. In the future, vaccines may have an important place in reducing the incidence of chickenpox in the population or, through the vaccination of middle-aged individ- Postherpetic Neuralgia 81 uals, in boosting immunity to varicella zoster virus, thus preventing or modifying the replication of the virus from its latent phase that results in herpes zoster. Developments in the understanding of the pathophysiology of PHN indicate possible directions for improved drug management of established PHN, although no evidence yet exists for efficacy of the drugs concerned. Such agents include new generation anticonvulsants and N-methyl-D-aspartate antagonists. Established postherpetic neuralgia (PHN) is re­ incidence of herpes zoster is between l.31[1] and markably intractable to therapy, leading to much 4.8[2] per 1000 per year in the population overall, distress and impaired quality of life for the pa­ and increases significantly with advancing age.[1 .3] tient, and significant costs to the healthcare pro­ Herpes zoster is caused by the reactivation and vider. The benefits of preventive therapy and treat­ spread of latent varicella zoster virus that has been ment for established PHN are difficult to assess, present since an earlier attack of varicella (chicken­ partly because there is no accepted definition of pox). It most commonly occurs because of a nat­ PHN, but also because there is a paucity of well ural decline in cell mediated immunity, secondary designed clinical trials. Complications of herpes to immunosenescence, but may occur in healthy zoster (shingles) other than PHN, though less com­ young people (fig. 1).[3.4] mon, are also important. Dissemination, secondary Reduced immunity may also occur secondary to infection, visual impairment and motor involvement disease or its treatment. For example, lymphomas are common; the latter two may be permanent. and their therapy, HIV infection, and the use of This review summarises current beliefs, and evi­ immunosuppressant drugs following organ trans­ dence where available, regarding predictors for the plant are commonly accompanied by herpes zoster. development of PHN and preventive measures that Long term use of anti-inflammatory steroids may can be taken during the acute phase of herpes zos­ also increase risk. Although immunosuppression is ter. Should PHN become established, a number of an important cause of herpes zoster, immuno­ therapies offer some chance of benefit but none is suppressed patients form a small proportion of universally effective. In this article, we give an those developing the condition. overview of suggested treatments. Pain is a feature of prodromal, acute-phase her­ pes zoster and a variable period of time following 1. The Size of the Problem rash healing. Figure 2 shows an estimate of the in­ cidence of pain during the continuum of zoster-as­ Epidemiological studies have shown that the sociated pain (Z-aP). 80 - de Moragas & Kierland[5[ ~ --- Hope-Simpson[6] 2. Zoster-Associated Pain and c 60 'Cij a. Postherpetic Neuralgia (PHN) -=. ~ 40 (f) PHN has been defined in many ways. Common C .!!? 20 , , definitions include: "iii , , fl. ------- • pain present after rash healing 0 1 0-19 20-29 30-39 40-49 50-59 60-69 70-79 ~ 80 • pain present 30 days after rash appearance Age (y) • pain present at 3 months Fig. 1. Incidence of postherpetic neuralgia (defined as pain per­ • pain present at 6 months. sisting for 1 month or more after rash onset) by age group. De­ Although a universally accepted definition has rived from data originally reported by de Moragas and Kierland[5] (from a 916-patient survey) and Hope-Simpson[6] (a 321-patient not been arrived at,[7] it is essential that all pub­ survey). with permission. lished work should state which definition has been © Adis International Lirnited. All rights reserved. Drugs & Aging 1997 Feb: 10 (2) 82 Johnson 100 Prodrome Acute phase Early PHN Late PHN or not patients developed PHN may have been in­ fluenced by treatment rather than a reflection of the natural course of the illness. 4. Prevention of PHN From our (incomplete) knowledge of the fac­ tors involved in Z-aP, it seems logical that limiting viral damage, reducing the inflammatory response and preventing ischaemic changes might prevent o -28 o 0 28 1 5 Days Days Months Years ongoing pain. Attention to the psychosocial factors Time after rash appearance associated with pain might help to place a patient on a more favourable curve of Dworkin's proposed Fig. 2. Estimated incidence of zoster-associated pain with time diathesis stress model for zoster pain[17] (fig. 3). before and after rash appearance.1261 By permission of Advan­ star Communications, reprinted from Neurology. Neurology is a Three preventive measures often applied are the registered trade mark of the American Academy of Neurology. acute-phase use of antiviral drugs, the acute-phase Abbreviation: PHN = postherpetic neuralgia. use of anti-inflammatory steroids and the early use of sympathetic nerve blockade (SNB). In addition, used. Where possible, the data should be analysed the early use of certain tricyclic antidepressants (e.g. using the commonly accepted definitions.[8] amitriptyline) may prevent PHN (D. Bowsher, per­ Z-aP is a term of convenience that encompasses sonal communication). the continuum of pain at all stages of the disease.[9] 5. Treatment of Acute Herpes Zoster 3. Risk Factors for PHN 5.1 Antiviral Agents Apart from increasing age,[I,IO] studies have shown that prodromal pain,[II] the severity of acute­ Herpes viruses are enveloped icosahedral struc­ phase pain, and psychosocial factors are important tures containing double-stranded DNA. Viral rep­ predictors of ongoing pain.[12-14] Rash severity has lication may be aborted by the use of antiviral drugs. been shown to be a predictor only in some stud­ Early anti herpes drugs (vidarabine, idoxuridine) ies.[IS] Higa and colleagues[16] have analysed data were of limited clinical use because of their toxic­ from 1431 patients with respect to age, involved ity. Newer drugs, such as aciclovir, are relatively region and severity of skin lesions at the worst phase. They showed that the duration of acute herpetic pain was indeed longer in elderly patients High and those with trigeminal zoster, but significantly Psychosocial more so in those with more severe skin lesions. Istress Severity of skin lesions is suggested as an indi­ Minimal cator of disease severity. However, patients with little or no acute pain and, similarly, those with insignificant rash may still develop PHN. It is not reliably known whether there is an increased risk Low High of PHN in immunocompromised patients or those Severity of infection-induced with ophthalmic zoster. Evaluation of predictors neuronal damage other than age is highly dependent on study design Fig. 3. Diathesis-stress model of postherpetic neuralgia, indicat­ and methods of data collection. In some studies ing the influence of psychosocial stress for a given extent of from which conclusions have been drawn, whether pathological damage.1171 © Adis International Lirnited. All rights reserved. Drugs & Aging 1997 Feb; 10 (2) Post herpetic Neuralgia 83 free of toxic effects at clinically relevant dosages, difficult to justify where a placebo control has been and are valuable in disease management. I shall used, because antiherpetic drugs significantly has­ only comment on their use in the management of ten rash healing compared with placebo. herpes zoster and their effects on Z-aP. Others have analysed data only from patients Aciclovir, valaciclovir and famciclovir work via a with pain 30 days after rash appearance (one of similar mechanism. After absorption from the gastro­ the definitions of PHN; see section 2). This takes intestinal tract, they are activated by phosphorylation account of the fact that spontaneous resolution of by virus-specific thymidine kinase (which is present pain is common up to this time. In a recent arti­ only in infected cells), and then further phosphory­ c1e,[SI Wood et al. discussed the ideal design of a lated by cellular enzymes. They are then incorporated clinical trial in herpes zoster infection. The authors into viral DNA chains, preventing replication. The agreed, among other things, the need for prospec­ oral bioavailability of aciclovir is poor, hence the tively agreed definitions of all outcome measures need for 5-times-daily administration of high doses.
Load more

Recommended publications
  • Treating Herpes Zoster and Postherpetic Neuralgia
    ® VOVOLL XX I XXIII• NO 1• NO• JU 4N E• MAY2013 2015 Treating Herpes Zoster and Postherpetic Neuralgia Vol.ÊXXI,ÊIssueÊ1Ê JuneÊ2013 Editorialostherpetic Board neuralgia (PHN) but a minority of patients experience months and 15% had pain at 2 years in is the most frequent chronic pain (PHN) persisting for months, years, a Dutch study.6 In the landmark zoster Editor-in-Chief PsychosocialÊAspectsÊofÊChronicÊPelvicÊPain complication of herpes zoster or even a lifetime. vaccine study, which included almost JaneÊC.ÊBallantyne,ÊMD,ÊFRCA (shingles).1 Herpes zoster (HZ) Anesthesiology,ÊPainÊMedicine 40,000 people aged 60 years or older PUSA represents a reactivation of the vari- Epidemiology of HZ and PHN (of whom fewer than 1000 developed cella zoster virus (VZV), a ubiquitous, Pain is unwanted, is unfortunately common, and remains essential for survival (i.e., AdvisoryÊBoard HZ) and where PHN was defined as highly neurotropic, exclusively human Accordingevading toda ang recenter) and systematic facilitating medical diagnoses. This complex amalgamation of MichaelÊJ.ÊCousins,ÊMD,ÊDSC pain intensity of 3/10 or more, 30% of -herpesvirus. Primary infection causes review,sensati theon, incidence emotions, of a ndHZ t houghis 3–5 ts manifests itself as pain behavior. Pain is a moti- α PainÊMedicine,ÊPalliativeÊMedicine 1patients who developed HZ had PHN - Australia casesvati perng f1000actor person-years.for physician 3c Theonsu ltations and for emergency department visits and is varicella (chickenpox), after which VZV at 1 month, 12% at 3 months, and 5% age-specific incidence rates of HZ were becomes latent in sensory ganglia along at 6 months in the placebo group.7 Ac- similar across countries, with a steep the entire neuraxis.
    [Show full text]
  • Update on Herpes Zoster: Treatment and Prevention of Shingles 27Th Annual Primary Health Care of Women Conference
    UPDATE ON HERPES ZOSTER: TREATMENT AND PREVENTION OF SHINGLES 27TH ANNUAL PRIMARY HEALTH CARE OF WOMEN CONFERENCE DECEMBER 5, 2019 PAMELA G. ROCKWELL, DO, FAAFP ASSOCIATE PROFESSOR DEPARTMENT OF FAMILY MEDICINE UNIVERSITY OF MICHIGAN NO FINANCIAL DISCLOSURES • AAFP Liaison of the Advisory Committee on Immunization Practices (ACIP) • AAFP Liaison ACIP Hepatitis, Pediatric and Adult RSV, and General Recommendations Work Groups • MAFP Liaison MDHHS Immunizations Committee • Co-Chair Immunization Committee, University of Michigan GOALS AND OBJECTIVES • Review Varicella Zoster Virus infection • Review Herpes Zoster (Shingles) Disease & Epidemiology • Review Shingles Risk Factors & Complications • Learn How to Diagnose and Treat Shingles and Common Complications • Learn How to Best Prevent Shingles/Update on Vaccination VARICELLA ZOSTER VIRUS (VZV) • Human α-herpesvirus, present worldwide, highly infectious • Primary infection with VZV causes varicella (chicken pox) • CDC estimate: ~ 4 million cases annually prior to 1995 • Annual incidence15-16 cases per 1,000 U.S. population • High annual burden of disease with hospitalization • 100-150 deaths per year https://www.cdc.gov/chickenpox/about/index.html CHICKENPOX • Transmitted person to person by direct contact, inhalation of aerosols from vesicular fluid of skin lesions of acute varicella or zoster (shingles), or aerosolized infected respiratory tract secretions CHICKENPOX • >95% of people born before 1980 in the U.S infected with wild-type VZV despite having no recall of disease* • VZV remains
    [Show full text]
  • Non-Live Recombinant Herpes Zoster Vaccine (SHINGRIX)
    Rx Files: Q&A Summary www.RxFiles.ca - Updated May 2021 Originally prepared by: M Jin, PharmD Non-Live Recombinant Herpes Zoster Vaccine (SHINGRIX) P L Bottom Line… SHINGRIX is indicated for the prevention of herpes zoster (HZ or shingles) in adults age ≥ 50 SHINGRIX reduces the risk of shingles by 91% (ARR=3.1%, NNT=32) & postherpetic neuralgia (PHN) by ~90% (ARR=0.30%, NNT=333) in 3 yrs. NNT: Eg. for every 333 vaccinated with SHINGRIX, 10 shingle cases (age ≥ 50 years) and 1 PHN cases (age ≥50 years) were prevented over ~ 3 yrs. SHINGRIX demonstrated efficacy for prevention of shingles effective in all age groups 50-80+. ZOSTAVAX less effective with increasing age. SHINGRIX use in patients with a history of shingles has been studied {open-label, non-randomized trial (n=93 patients, age 50-89 yr) for 3 months}.ZOSTER-033 Vaccine can be given after shingles symptoms/rash resolved CDC or ≥1 yr CDN Cost ~ $ 300 for 2 doses given intramuscularly (IM) 2-6 months apart (can give up to 12 months apart if needed to increase compliance). (Refrigerate 2 to 8°C; Discard if frozen) (New Jan/2021 NIHB covers for those between 65 & 70 years of age) Canadian NACI’18 recommends SHINGRIX should be offered to individuals ≥50 yrs without contraindications including: -Individuals previously vaccinated with ZOSTAVAX or ZOSTAVAX II; Re-vaccinate with two doses of RZV at least one year after receiving ZOSTAVAX -Individuals with a previous episode of herpes zoster disease. Provide two doses of SHINGRIX at least one year after herpes zoster episodeexpert opinion -Immunocompromised individuals, may be considered on a case-by-case assessment of the benefits vs risks expert opinion ZOSTAVAX II may be considered for immunocompetent individuals ≥50 yrs without contraindications when SHINGRIX is contraindicated, unavailable or inaccessible.
    [Show full text]
  • View Board (KMUH-IRB-EXEMPT- We Further Investigated Whether HF Is a Time- 20130059)
    Wu et al. BMC Infectious Diseases (2015) 15:17 DOI 10.1186/s12879-015-0747-9 RESEARCH ARTICLE Open Access A nationwide population-based cohort study to identify the correlation between heart failure and the subsequent risk of herpes zoster Ping-Hsun Wu1,4, Yi-Ting Lin2, Chun-Yi Lin6, Ming-Yii Huang3, Wei-Chiao Chang5,7 and Wei-Pin Chang6* Abstract Background: The association between heart failure (HF) and herpes zoster has rarely been studied. We investigated the hypothesis that HF may increase the risk of herpes zoster in Taiwan using a nationwide Taiwanese population- based claims database. Method: Our study cohort consisted of patients who received a diagnosis of HF in 2001 ~ 2009 (N = 4785). For a comparison cohort, three age- and gender-matched control patients for every patient in the study cohort were selected using random sampling (N = 14,355). All subjects were tracked for 1 year from the date of cohort entry to identify whether or not they had developed herpes zoster. Cox proportional-hazard regressions were performed to evaluate 1-year herpes zoster-free survival rates. Results: The main finding of this study was that patients with HF seemed to be at an increased risk of developing herpes zoster. Of the total patients, 211 patients developed herpes zoster during the 1-year follow-up period, among whom 83 were HF patients and 128 were in the comparison cohort. The adjusted hazard ratio (AHR) of herpes zoster in patients with HF was higher (AHR: 2.07; 95% confidence interval (CI): 1.54 ~ 2.78; p < 0.001) than that of the controls during the 1-year follow-up.
    [Show full text]
  • Volume 27 • Number 1 • 2010
    Newsletter A publication of the Controlled Release Society Volume 27 • Number 1 • 2010 What’s Inside New C&DP Representative Joins Newsletter Board Portland Awaits Phase Separation Behavior of Fusidic Acid in Microspheres Tailoring In Vitro Cell Responses of Porous Silicon Nanoencapsulation Using Microfluidizer® Processors Gamma Scintigraphy and Canine Respiratory Models News from the CRS Focus Groups CRS-AAPS Workshop a Success C&DP Patent Watch IT’S ALL ABOUT THE CONTENT That’s why subscribers of Drug Delivery Technology spend 40 minutes reading each issue. Drug Delivery Technology is the only publication completely dedicated to product development. Highlight your message to our 20,000 subscribers through print and online marketing opportunities! Y 10 printed issues Y eNewsletter sent twice per month, featuring the latest news CONTACT US TODAY shaping the industry (lim ited to 5 sponsors per month) EAST & MIDWEST Victoria Geis • Tel: (703) 212- 7735 • [email protected] Y Website Banner Advertising WEST Y Webinars and webcasts Warren DeGraff • Tel: (415) 721-0664 • [email protected] INTERNATIONAL Y Listings in the Resource Directory Ralph Vitaro • Tel: (973) 263-5476 • [email protected] (All listings in print and the digital WEBINARS version posted online) Michael J. Masters • 973-299-1200 • [email protected] Newsletter Steven Giannos Vol. 27 • No. 1 • 2010 Editor Table of Contents From the Editor .................................................................................................................
    [Show full text]
  • Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines
    Morbidity and Mortality Weekly Report Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines Kathleen L. Dooling, MD1; Angela Guo, MPH1; Manisha Patel, MD1; Grace M. Lee, MD2; Kelly Moore, MD3; Edward A. Belongia, MD4; Rafael Harpaz, MD1 Introduction Methods On October 20, 2017, Zoster Vaccine Recombinant, From March 2015 to October 2017, the ACIP Herpes Adjuvanted (Shingrix, GlaxoSmithKline, [GSK] Research Zoster Vaccines Work Group (Work Group; see acknowl- Triangle Park, North Carolina), a 2-dose, subunit vaccine edgments for members and their affiliations) participated containing recombinant glycoprotein E in combination with in monthly or bimonthly teleconferences to review herpes a novel adjuvant (AS01B), was approved by the Food and zoster epidemiology and the evidence for the efficacy, safety, Drug Administration for the prevention of herpes zoster in and programmatic factors of RZV and ZVL. According to adults aged ≥50 years. The vaccine consists of 2 doses (0.5 mL the Grading of Recommendations Assessment, Development each), administered intramuscularly, 2–6 months apart (1). On and Evaluation (GRADE) approach, the Work Group defined October 25, 2017, the Advisory Committee on Immunization critical and important outcomes, conducted a systematic Practices (ACIP) recommended the recombinant zoster vaccine review of the evidence, and subsequently reviewed and dis- (RZV) for use in immunocompetent adults aged ≥50 years. cussed findings and evidence quality (https://www.cdc.gov/ Herpes zoster is a localized, usually painful, cutaneous erup- vaccines/acip/recs/grade/) (9). tion resulting from reactivation of latent varicella zoster virus A cost effectiveness analysis comparing RZV, ZVL, or no (VZV).
    [Show full text]
  • Communicable Disease (CD) Quarterly Report San Francisco Department of Public Health 2018 Quarter 2 • November 26, 2018
    Communicable Disease (CD) Quarterly Report San Francisco Department of Public Health 2018 Quarter 2 • November 26, 2018 Disease Reporting: 415-554-2830 (phone); 415-554-2848 (fax); http://www.sfcdcp.org Tomás Aragón, MD, DrPH, Health Officer Juliet Stoltey, MD, MPH, Director, Communicable Disease Control and Prevention The Communicable Disease Control Unit receives and responds to reports of communicable diseases. For urgent reports during business hours, please call (415) 554-2830. For urgent or emergent reports after hours, please call (415) 554-2830 and follow instructions to contact the on-call physician. For non-urgent reports, please fax a Confidential Morbidity Report (CMR) to (415) 554-2848. Please see our website for more information: http://www.sfcdcp.org Sign up to receive Health Alerts at: https://www.sfcdcp.org/health-alerts-emergencies/health-alerts/register-for-health-alerts/ Table 1: Number of Selected Reported Communicable Disease Cases Current Recommendations for Shingles Prevention 2018 2017 Herpes zoster, or shingles, is a painful vesicular rash caused by reactivation of Q2 Q1-Q2 Q2 Q1-Q2 the varicella-zoster virus (VZV, the virus that causes chickenpox). The rash most commonly occurs in a dermatomal distribution and usually heals in 2-4 weeks. Botulism 0 0 1 1 In 10-13% of cases over age 50, a painful postherpetic neuralgia develops that Invasive Meningococcal Disease 0 0 0 0 may last for weeks, months, and occasionally, years. Risk of shingles increases # with age; CDC estimates a 50% lifetime risk in persons living to age 85. Altered Meningitis— Bacterial 1 4 4 6 immunocompetence increases the risk for shingles as well as risk of severe Meningitis— Viral 7 9 2 4 complications.
    [Show full text]
  • Budget-Impact Analysis of Alternative Herpes Zoster Vaccine Strategies: a U.S
    RESEARCH Budget-Impact Analysis of Alternative Herpes Zoster Vaccine Strategies: A U.S. HMO Perspective Jonathan Graham, BS; Josephine Mauskopf, PhD; Kosuke Kawai, ScD; Kelly D. Johnson, PhD, MPH; Ruifeng Xu, PhD; and Camilo J. Acosta, MD, PhD, MSc ABSTRACT driven primarily by vaccination costs. The results of the scenario analyses BACKGROUND: A herpes zoster vaccine has been approved by the FDA for showed that lower vaccination costs because of the application of copay- use in prevention of herpes zoster in individuals who are aged 50 years or ments for a managed care organization reduced the magnitude of the total older. The Advisory Committee on Immunization Practices (ACIP) recom- cost increase associated with the increase in uptake. mends vaccination only in individuals who are aged 60 years and older. CONCLUSIONS: Vaccinating individuals aged 50 to 59 years with the herpes zoster vaccine would likely have an impact on a health plan’s budget OBJECTIVES: To (a) estimate the overall budget and health impact of either because of the expected increase in the total number of individuals being the introduction of a new vaccination strategy (individuals over the age vaccinated in the population, with limited cost savings because of fewer of 50 years vs. individuals over the age of 60 years) within a hypothetical cases of herpes zoster. Higher coverage of vaccinations resulted in a greater health plan or simply an increase in coverage within the population aged increase in total costs each year. However, increasing coverage would also 60 years and over and (b) discern what effect copayments and changes to result in a decrease in the number of individuals developing zoster and copayments have on the health plan’s budget.
    [Show full text]
  • Recombinant Zoster (Shingles) Vaccine
    VACCINE INFORMATION STATEMENT Many Vaccine Information Statements are available in Spanish and other languages. Recombinant Zoster (Shingles) See www.immunize.org/vis Hojas de información sobre vacunas están disponibles en español y en muchos otros Vaccine: What You Need to Know idiomas. Visite www.immunize.org/vis 1 Why get vaccinated? Recombinant shingles 2 vaccine Recombinant zoster (shingles) vaccine can prevent shingles. Recombinant shingles vaccine provides strong protection against shingles. By preventing shingles, Shingles (also called herpes zoster, or just zoster) is recombinant shingles vaccine also protects against a painful skin rash, usually with blisters. In addition PHN. to the rash, shingles can cause fever, headache, chills, or upset stomach. More rarely, shingles can lead Recombinant shingles vaccine is the preferred to pneumonia, hearing problems, blindness, brain vaccine for the prevention of shingles. However, a inflammation (encephalitis), or death. different vaccine, live shingles vaccine, may be used in some circumstances. The most common complication of shingles is long-term nerve pain called postherpetic neuralgia The recombinant shingles vaccine is recommended (PHN). PHN occurs in the areas where the shingles for adults 50 years and older without serious rash was, even after the rash clears up. It can last for immune problems. It is given as a two-dose series. months or years after the rash goes away. The pain This vaccine is also recommended for people who from PHN can be severe and debilitating. have already gotten another type of shingles vaccine, the live shingles vaccine. There is no live virus in this vaccine. Shingles vaccine may be given at the same time as other vaccines.
    [Show full text]
  • Postherpetic Neuralgia
    Journal of Pain & Palliative Care Pharmacotherapy. 2011;25:187–189. Copyright © 2011 Informa Healthcare USA, Inc. ISSN: 1536-0288 print / 1536-0539 online DOI: 10.3109/15360288.2010.550990 PATIENT EDUCATION AND SELF-ADVOCACY: QUESTIONS AND RESPONSES ON PAIN MANAGEMENT Edited by Yvette Colon´ Postherpetic Neuralgia Naileshni Singh ABSTRACT Questions from patients about analgesic pharmacotherapy and responses from authors are presented to help educate patients and make them more effective self-advocates. The topic addressed in this issue is postherpetic neuralgia, symptoms, risk factors, and treatment. KEYWORDS acyclovir, capsaicin, corticosteroids, herpes zoster, lidocaine, neuropathic analgesics, posther- petic neuralgia, shingles, varicella-zoster QUESTION FROM A PATIENT tion and the chronic pain syndrome of postherpetic neuralgia. In their youth, many people have had I had shingles earlier in the year and thought I re- chicken pox, which is caused by the same virus, covered well, but I still have a lot of pain. My doctor called varicella-zoster. After this first infection, it is calls it postherpetic neuralgia. What are the best treat- thought that the virus lies within the sensory nerves For personal use only. ments for it and how can I get rid of the pain? I’m 57 in the spinal cord. With older age or in patients with years old and in fairly good health otherwise. poor immune systems, the virus can often “reacti- vate” and cause a rash accompanied by pain. The pain may subside, but in certain instances, individ- Answer uals may develop persistent pain that can last for sev- Postherpetic neuralgia (PHN) can be an unfortunate eral years.
    [Show full text]
  • Full Prescribing Information 1 Indications and Usage Zostavax
    HIGHLIGHTS OF PRESCRIBING INFORMATION Transmission of vaccine virus may occur between vaccinees and These highlights do not include all the information needed to use susceptible contacts (5.2) ZOSTAVAX safely and effectively. See full prescribing information Deferral should be considered in acute illness (for example, in the for ZOSTAVAX. presence of fever) or in patients with active untreated tuberculosis (5.3) ZOSTAVAX® (Zoster Vaccine Live) Avoid pregnancy for 3 months following vaccination with Suspension for subcutaneous injection ZOSTAVAX (8.1) Initial U.S. Approval: 2006 ------------------------------ ADVERSE REACTIONS ------------------------------ ----------------------------INDICATIONS AND USAGE ---------------------------- The most frequent adverse reactions, reported in ≥1% of subjects ZOSTAVAX is a live attenuated virus vaccine indicated for prevention vaccinated with ZOSTAVAX, were headache and injection-site of herpes zoster (shingles) in individuals 50 years of age and older. (1) reactions. (6) Limitations of Use of ZOSTAVAX: To report SUSPECTED ADVERSE REACTIONS, contact Merck ZOSTAVAX is not indicated for the treatment of zoster or Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., at 1-877- postherpetic neuralgia (PHN) (1) 888-4231 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov. ZOSTAVAX is not indicated for prevention of primary varicella infection (Chickenpox) (1) -------------------------------DRUG INTERACTIONS------------------------------- In a randomized clinical study, a reduced immune response to ----------------------- DOSAGE AND ADMINISTRATION------------------------ ZOSTAVAX as measured by gpELISA was observed in individuals Single 0.65 mL subcutaneous injection (2.1) who received concurrent administration of PNEUMOVAX® 23 and ZOSTAVAX compared with individuals who received these vaccines 4 --------------------- DOSAGE FORMS AND STRENGTHS --------------------- weeks apart. Consider administration of the two vaccines separated by Single dose vials with not less than 19,400 plaque-forming units [PFU] at least 4 weeks.
    [Show full text]
  • Book Review Editorial
    BookEditorial Review Two Ounces of Prevention Jeffrey M. Weinberg, MD iven the morbidity and treatment challenges Herpes zoster is another disease for which a new posed by many disease states, prevention of vaccine is in development. The incidence and severity G those conditions clearly would be a preferable of this condition and the associated postherpetic neu- alternative. Over the past year, we have observed exam- ralgia increases with age, and we have an increasingly ples of progress in this direction, especially in the field aging population. Oxman et al3 conducted a large study of infectious diseases. The 2 most recent prevention to determine if vaccination against varicella-zoster strategies will have direct relevance to dermatologists. virus would decrease the incidence, severity, or both of In October 2005, Merck announced that an inves- herpes zoster and postherpetic neuralgia among older tigational vaccine (quadrivalent human papillo- adults. They enrolled 38,546 subjects 60 years or mavirus [HPV] types 6, 11, 16, and 18, recombinant older in a randomized, double-blind, placebo-controlled vaccine) prevented 100% of high-grade cervical pre- trial of an investigational live attenuated Oka/Merck cancers and noninvasive cervical cancers associated varicella-zoster virus vaccine (“zoster vaccine”). The with HPV types 16 and 18 in a recent phase 3 study pain and discomfort associated with herpes zoster were (PϽ.001).1 The analysis compared the vaccine to measured repeatedly for 6 months. The primary end placebo in women who were not infected with HPV point was the burden of illness due to herpes zoster, a types 16 and 18 at enrollment and who remained free measure affected by the incidence, severity, and dura- of infection through the completion of the vaccina- tion of the associated pain and discomfort.
    [Show full text]